18 Bone metabolism Flashcards
18.01 ANTIRESORPTIVE DRUGS
Bisphosphonates: alendronate, zoledronate, pamidronate, risedronate - actions
decrease bone resorption and increase bone density
18.01 ANTIRESORPTIVE DRUGS
Bisphosphonates: alendronate, zoledronate, pamidronate, risedronate - MOA
anchor to cell surface proteins on osteoclast membrane by prenylation
prevent osteoclast-mediated bone resorption
incorporated into the bone matrix and ingested by osteoclasts, promoting osteoclast apoptosis
18.01 ANTIRESORPTIVE DRUGS
Bisphosphonates: alendronate, zoledronate, pamidronate, risedronate - abs/distrib/elim
alendronate, ibandronate, risedronate: given orally with a large amount of water 30min before eating
IV formulations of ibandronate, zoledronate and pamidronate are available
about 50% of absorbed drug accumulates at sites of bone mineralisation, where it remains absorbed onto hydroxyapatite crystals, potentially for months or years, until the bone is resorbed
the free drug is excreted unchanged by the kidneys
18.01 ANTIRESORPTIVE DRUGS
Bisphosphonates: alendronate, zoledronate, pamidronate, risedronate - clinical use
prevention and treatment of osteoporosis
hypercalcaemia
advanced malignancies with bone metastases
pain relief in Paget’s disease of bone
18.01 ANTIRESORPTIVE DRUGS
Bisphosphonates: alendronate, zoledronate, pamidronate, risedronate - adverse effects
GIT disturbances, particularly oesophagitis (patient should remain upright for 30min after administration to reduce reflux)
bone pain
osteonecrosis of the jaw (rare) - zoledronate is most potent and more likely to cause osteonecrosis (dental checks and remedial dental work are prerequisites)
atypical femoral fractures with long-term treatment
18.02 ANTIRESORPTIVE DRUGS
Selective oestrogen receptor modulators (SERMs): raloxifene - actions
agonist effects on bone and on the CVS but antagonist action on mammary glands and the uterus
18.02 ANTIRESORPTIVE DRUGS
Selective oestrogen receptor modulators (SERMs): raloxifene - MOA
like the oestrogens, it inhibits the cytokines that recruit osteoclasts
18.02 ANTIRESORPTIVE DRUGS
Selective oestrogen receptor modulators (SERMs): raloxifene - abs/distrib/elim
given orally
undergoes first-pass metabolism
bioavailability ~2%
plasma half-life ~32h
18.02 ANTIRESORPTIVE DRUGS
Selective oestrogen receptor modulators (SERMs): raloxifene - clinical use
prophylaxis for postmenopausal osteoporosis and breast cancer
18.02 ANTIRESORPTIVE DRUGS
Selective oestrogen receptor modulators (SERMs): raloxifene - adverse effects
risk of thromboembolism
18.03 ANTIRESORPTIVE DRUGS
Calcitonin - actions
lowers serum calcium levels and decreases bone resorption
18.03 ANTIRESORPTIVE DRUGS
Calcitonin - MOA
decreases calcium and phosphate reabsorption in the kidney
inhibits bone resorption by binding to a specific receptor on osteoclasts, inhibiting their action
18.03 ANTIRESORPTIVE DRUGS
Calcitonin - abs/distrib/elim
given by SC/IM injection or nasal spray
plasma half-life 4-12 min
action lasts several hours
18.03 ANTIRESORPTIVE DRUGS
Calcitonin - clinical use
hypercalcaemia
Paget’s disease
prevention of postmenopausal osteoporosis
18.03 ANTIRESORPTIVE DRUGS
Calcitonin - adverse effects
GIT disorders
facial flushing
taste disturbances
dizziness
muscle pain